Year: 2012
Type: letter
Abstract: REPLY: The work that we have recently described tested the feasibility of the use of Affibody molecules (Affibody AB) and PET to predict tumor response to ErbB2-targeted therapy. It is clear that additional studies will be needed to dissect the mechanistic events underlying the observed changes.
Source: Journal of Nuclear Medicine
Institution: National Institutes of Health
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2326264021